Dose-Response at 24 Weeks The 24-week data illustrate the dose-response relationship during the mid-treatment phase: Phase 3 Results: Extended Timeline Data TRIUMPH-4 (68 Weeks) The TRIUMPH-4 Phase 3 trial extended the treatment duration to 68 weeks in 445 adults with obesity and knee osteoarthritis
Reviews No matching reviews Try clearing or changing the filters Every product undergoes our Healf Curation Process
This combination helps people naturally reduce how much they eat without feeling as hungry." GLP-1 medications, also known as GLP-1 receptor agonists, mimic this hormone to help treat type 2 diabetes and obesity , says Lauren Harris-Pincus, MS, RDN, founder of NutritionStarringYOU.com and author of The Everything Easy Pre-Diabetes Cookbook
Jenkins DJ, Wolever TM, Collier GR, Ocana A, Rao AV, Buckley G, et al